People
BlueRock Therapeutics names new board chair
27 July 2021 -

BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced on Monday that it has named Emile Nuwaysir, PhD as its new board chair, effective 1 August 2021.

Presently, Nuwaysir is the BlueRock Therapeutics president and CEO. He joined the company in 2020. The company said that he has experience building a small biotech and deep understanding of how to work and thrive within a large pharmaceutical ecosystem. He has brought various cellular therapies from invention to clinical testing.

In the new role, Dr Nuwaysir will continue to take an active role in the growth and maturation of the company, offering guidance and support on both corporate strategy and R&D.

Login
Username:

Password: